Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Flavio Cadegiani
AJP Endocrinology and Metabolism (2020) Vol. 318, Iss. 5, pp. E587-E588
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Drug repurposing for COVID-19: Approaches, challenges and promising candidates
Yan Ling Ng, Cyrill Kafi Salim, Justin Jang Hann Chu
Pharmacology & Therapeutics (2021) Vol. 228, pp. 107930-107930
Open Access | Times Cited: 133
Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?
Rosario Pivonello, Renata S. Auriemma, Claudia Pivonello, et al.
Neuroendocrinology (2020) Vol. 111, Iss. 11, pp. 1066-1085
Open Access | Times Cited: 124
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
Flavio Cadegiani, John McCoy, Carlos Gustavo Wambier, et al.
Cureus (2021)
Open Access | Times Cited: 66
Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials
Rami A. Al‐Horani, Srabani Kar, Kholoud F. Aliter
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5224-5224
Open Access | Times Cited: 58
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier
Medical Hypotheses (2020) Vol. 143, pp. 110112-110112
Open Access | Times Cited: 57
Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
Flavio Cadegiani, Carlos Gustavo Wambier, Andy Goren
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 49
Repurposing existing drugs for COVID-19: an endocrinology perspective
Flavio Cadegiani
BMC Endocrine Disorders (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 45
Coronavirus and Cardiometabolic Syndrome
Jeffrey I. Mechanick, Robert S. Rosenson, Sean Pinney, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 17, pp. 2024-2035
Open Access | Times Cited: 45
Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2
Lucia Lisi, Pedro Miguel Lacal, Maria Luisa Barbaccia, et al.
Biochemical Pharmacology (2020) Vol. 180, pp. 114169-114169
Open Access | Times Cited: 41
Profil clinique, biologique et radiologique des patients Algériens hospitalisés pour COVID-19: données préliminaires
A. Ketfi, Omar Chabati, S. Chemali, et al.
Pan African Medical Journal (2020) Vol. 35, Iss. Supp 2
Open Access | Times Cited: 31
Understanding COVID-19: Digit ratio (2D:4D) and sex differences in national case fatality rates
John T. Manning, Bernhard Fink
Early Human Development (2020) Vol. 146, pp. 105074-105074
Open Access | Times Cited: 29
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
New Microbes and New Infections (2021) Vol. 43, pp. 100915-100915
Open Access | Times Cited: 27
Consideration of Pannexin 1 channels in COVID-19 pathology and treatment
Leigh Anne Swayne, Scott R. Johnstone, Chen Seng Ng, et al.
AJP Lung Cellular and Molecular Physiology (2020) Vol. 319, Iss. 1, pp. L121-L125
Open Access | Times Cited: 26
Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?
Berta Soldevila, Manel Puig‐Domingo, Mónica Marazuela
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 23, Iss. 2, pp. 137-150
Open Access | Times Cited: 22
ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study
María Íñiguez, Patricia Pérez‐Matute, Pablo Villoslada-Blanco, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 21
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Marco Vicenzi, Massimiliano Ruscica, Simona Iodice, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2943-2943
Open Access | Times Cited: 19
Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of Glycyrrhiza glabra L. (Licorice)
Decio Armanini, Cristina Fiore, Jens Bielenberg, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 17
Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
Research Square (Research Square) (2020)
Open Access | Times Cited: 14
Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 13
Use of Spironolactone in SARS-CoV-2 ARDS Patients
Güleren Yartaş Dumanlı, Olcay Dilken, Seval Ürkmez
Turkish Journal of Anaesthesiology and Reanimation (2020) Vol. 48, Iss. 3, pp. 254-255
Open Access | Times Cited: 12
Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19
Zakiye Nadeali, Fatemeh Mohammad-Rezaei, Hamid Aria, et al.
Life Sciences (2022) Vol. 297, pp. 120482-120482
Open Access | Times Cited: 8
A Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery
Rupa Mazumder, Kamal Kant Kaushik, Abhijit Debnath, et al.
Letters in Drug Design & Discovery (2022) Vol. 20, Iss. 3, pp. 264-278
Closed Access | Times Cited: 7
Shedding light on therapeutics in alopecia and their relevance to COVID-19
Nicole Fagan, Nekma Meah, Katherine York, et al.
Clinics in Dermatology (2020) Vol. 39, Iss. 1, pp. 76-83
Open Access | Times Cited: 9
An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 8
Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).
Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, et al.
Research Square (Research Square) (2020)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top